{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-321737","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.708862+00:00","generated_at":"2026-05-16T12:56:44.090455+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Coya receives $4.2M milestone from Dr. Reddy's for first ALS patient dosed","bullets":["Milestone triggered by first patient dosed in ALSTARS trial of COYA 302 for ALS.","Dosing announced Dec 9, 2025; payment received Dec 16, 2025.","Payment under Dec 2023 Development and License Agreement with Dr. Reddy's Labs.","COYA 302 is an investigational therapy targeting amyotrophic lateral sclerosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-321737","json":"https://secwatch.observer/filing/0001193125-25-321737.json","markdown":"https://secwatch.observer/filing/0001193125-25-321737.md","text":"https://secwatch.observer/filing/0001193125-25-321737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525321737/0001193125-25-321737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525321737/d729078d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:56:44.090455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}